Advanced Therapeutics最新文献

Zero-Order Delivery of Natamycin-Loaded Novel Nanoemulgel for Ocular Keratomycosis Management: Formulation and Optimization 新型纳他霉素纳米凝胶的零级递送：配方与优化

IF 3.2 4区医学

Advanced Therapeutics Pub Date : 2026-10-15 DOI: 10.1002/adtp.70181

Anjali Mishra, Manish Kumar, Manisha Bhatia, Giriraj T Kulkarni, Sanjeev Kumar

{"title":"Zero-Order Delivery of Natamycin-Loaded Novel Nanoemulgel for Ocular Keratomycosis Management: Formulation and Optimization","authors":"Anjali Mishra, Manish Kumar, Manisha Bhatia, Giriraj T Kulkarni, Sanjeev Kumar","doi":"10.1002/adtp.70181","DOIUrl":"https://doi.org/10.1002/adtp.70181","url":null,"abstract":"<div>\u0000 \u0000 <p>A promising delivery system is being investigated for better management of a highly neglected disease segment named keratomycosis, using nanoemulsion-based gels (nanoemulgels). They offer the potential to improve patient compliance, enhance drug penetration and efficacy, extend drug contact time, and reduce side effects compared to traditional eye drops. This investigation focused on the development of a nanoemulsion-based gel system to facilitate ocular delivery of Natamycin. Drug-loaded nanoemulgels were prepared using the ultrasonication method. These formulations then underwent assessment for particle size, drug loading capacity, drug release profile, in vitro permeation characteristics, and in vivo ocular irritation potential. The optimized nanoemulsion-based in situ gel (FNG4) showed superior ex vivo transcorneal permeation, with < 200 nm particle size, +26.3 ± 2.24 mV zeta potential, ∼89% residual drug content, and zero-order kinetics. It was found to be homogeneous and stable for use. In conclusion, an optimized pH-sensitive ocular formulation capable of treating keratomycosis along with overcoming the existing shortcomings was successfully developed.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 10","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quality-by-Design Guided Development and Evaluation of Tea Tree Oil-Based Tacrolimus-Loaded Nanostructured Carrier Gel for Psoriasis Therapy 茶树油基负载他克莫司纳米结构载体凝胶治疗银屑病的质量设计指导开发和评价

IF 3.2 4区医学

Advanced Therapeutics Pub Date : 2026-10-12 DOI: 10.1002/adtp.70180

Nitika Garg, Pankaj Popli, Sanchit Dhankhar, Kashish Wilson, Thakur Gurjeet Singh, Rajan Swami, Chander Parkash Dora

{"title":"Quality-by-Design Guided Development and Evaluation of Tea Tree Oil-Based Tacrolimus-Loaded Nanostructured Carrier Gel for Psoriasis Therapy","authors":"Nitika Garg, Pankaj Popli, Sanchit Dhankhar, Kashish Wilson, Thakur Gurjeet Singh, Rajan Swami, Chander Parkash Dora","doi":"10.1002/adtp.70180","DOIUrl":"https://doi.org/10.1002/adtp.70180","url":null,"abstract":"<div>\u0000 \u0000 <p>Psoriasis is a chronic skin disease primarily caused by inflammation, resulting in abnormal growth of epidermal cells that cause skin reddening, scaling, and irritation. Tacrolimus (TAC), a poorly soluble immunosuppressant drug, was used in the current study for the management of psoriasis. Moreover, tea tree oil (TTO) was also utilized as a functional excipient to synergize the efficiency of the drug. Here, nanostructured lipidic carriers (NLCs) were formulated using a high-shear homogenization method. To ensure a robust and scientifically optimized formulation, a Quality by Design (QbD) approach was implemented to systematically investigate the influence of formulation variables on critical quality attributes and to obtain an optimized nanoformulation. The developed nanocarriers showed 108.65 ±2.4 nm particle size, 0.265±0.028 polydispersity index, and <b>∼</b>23.9 mV zeta potential. Morphological examination revealed the spherical structure of nanoformulations with uniform distribution. Differential scanning colorimeter studies showed the absence of a crystalline state of the drug, when incorporated in the formulation. Furthermore, gel formulations of drug-embedded NLCs were characterized for pH, viscosity, and spreadability. In vivo model was used to elucidate the higher efficacy of the developed formulation. In this work, different studies highlight the potential of tacrolimus loaded novel gel including the complementary advantages of tea tree oil.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 10","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sonodynamic Molecules for Tumor Immunotherapy and Immunoimaging 用于肿瘤免疫治疗和免疫成像的声动力分子

IF 3.2 4区医学

Advanced Therapeutics Pub Date : 2026-10-07 DOI: 10.1002/adtp.70179

Ershuang Li, Baohui Yuan, Mengyun Liang, Ji Qi

{"title":"Sonodynamic Molecules for Tumor Immunotherapy and Immunoimaging","authors":"Ershuang Li, Baohui Yuan, Mengyun Liang, Ji Qi","doi":"10.1002/adtp.70179","DOIUrl":"https://doi.org/10.1002/adtp.70179","url":null,"abstract":"<div>\u0000 \u0000 <p>Sonodynamic therapy (SDT) has emerged as a promising cancer treatment modality owing to its noninvasive nature and deep tissue penetration capability. Beyond direct tumor ablation, SDT can modulate antitumor immunity, which drives the development of high-performance sonodynamic platforms for precise and potent immunoregulation. In this review, we summarize recent advances in molecular engineering strategies for developing intelligent sonosensitizers capable of orchestrating diverse immunological processes. These advanced platforms promote robust immunogenic cell death through enhanced reactive oxygen species generation, amplify immune activation by mimicking costimulatory signaling or integrating genetically engineered bacteria, enable ultrasound-triggered and in situ release of immune checkpoint inhibitors through responsive linkers, and potentiate STING signaling via responsive prodrug designs, thereby coordinating innate and adaptive immune responses. In addition, activatable acoustic afterglow probes have been developed for real-time visualization of immune-cell activity, tumor immune microenvironment dynamics, and SDT-induced immunogenic events, providing valuable feedback on therapeutic efficacy. Collectively, this review highlights the molecular design principles, functional mechanisms, and biomedical applications of engineered sonodynamic systems, guiding the development of next-generation platforms for precision cancer immunotherapy and immune imaging.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 10","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149100277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From Molecular Targets to Advanced Delivery Systems: Aptamers for Precision Ocular Therapeutics 从分子靶点到先进的输送系统：用于精确眼部治疗的适体

IF 3.2 4区医学

Advanced Therapeutics Pub Date : 2026-10-06 DOI: 10.1002/adtp.70178

Minal Thacker, Ka-Ying Wong, Liping Zhou, Man-Sau Wong, Juewen Liu

{"title":"From Molecular Targets to Advanced Delivery Systems: Aptamers for Precision Ocular Therapeutics","authors":"Minal Thacker, Ka-Ying Wong, Liping Zhou, Man-Sau Wong, Juewen Liu","doi":"10.1002/adtp.70178","DOIUrl":"https://doi.org/10.1002/adtp.70178","url":null,"abstract":"<p>Ocular disorders, ranging from anterior surface diseases to posterior segment pathologies present significant challenges and opportunities in therapeutic delivery. The unique anatomical and physiological barriers of the eye demand precision therapeutics that go beyond the limitations of traditional biologics. Aptamers, often termed “chemical antibodies,” have emerged as a transformative class of therapeutics, that circumvents these barriers. This review analyses critical molecular targets across major ocular diseases for example TNF-a, MMP9, and chemokines in dry eye disease; TGFβ2, GD15 in glaucoma; VEGF and complement components in age related macular degeneration and diabetic retinopathy as foundations for next generation aptamer-based therapeutic and diagnostic design. It also highlights the latest advancements in sustained-release delivery systems to address persistent challenges in ocular pharmacology, including overcoming ocular barriers, preventing rapid clearance, and improving bioavailability. Furthermore, the review addresses current translational barriers, including nuclease degradation, rapid ocular clearance, and complex regulatory hurdles that must be navigated to bring these therapies to clinical practice. As research progresses toward identifying disease-specific signatures, the high tunability and customization of aptamers offer a promising avenue for revolutionizing interventions in complex ocular conditions, ultimately signalling a shift toward more personalized and effective eye care.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 10","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.70178","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149099677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Histamine Receptor Agonists Differentially Modulate Wound Closure and Tissue Repair in Diabetic and Obese Mice 组胺受体激动剂对糖尿病和肥胖小鼠伤口愈合和组织修复的差异调节

IF 3.2 4区医学

Advanced Therapeutics Pub Date : 2026-10-06 DOI: 10.1002/adtp.202500588

Sudhakar Godeshala, Shubham Pallod, Lingchen Fu, Jordan R. Yaron, Kaushal Rege

{"title":"Histamine Receptor Agonists Differentially Modulate Wound Closure and Tissue Repair in Diabetic and Obese Mice","authors":"Sudhakar Godeshala, Shubham Pallod, Lingchen Fu, Jordan R. Yaron, Kaushal Rege","doi":"10.1002/adtp.202500588","DOIUrl":"https://doi.org/10.1002/adtp.202500588","url":null,"abstract":"<div>\u0000 \u0000 <p>Wound healing in diabetes is impaired, in part, because of poor angiogenesis as well as poor recruitment and dysfunction of immune cells. As a consequence, diabetic patients are at a higher risk of wound infections, dehiscence, and abnormal scarring, and these complications contribute to significant medical and economic burden globally. In early stages of healthy injury repair, mast cells release histamine, which acts via four histamine receptors (HRH) 1-4, and induces vascular permeability, thereby facilitating migration of immune cells into the wound microenvironment. In our previous studies, we have shown that individual agonism of histamine receptors in incisional, acute wounds differentially modulates healing. In the current study, we investigated the efficacy of selective small-molecule, histamine receptor agonists for wound closure and tissue repair in diabetic, obese mice. Here, topical delivery of HRH1 and HRH4 agonists, 2-pyridylethylamine and 4-methylhistamine, respectively, significantly accelerated wound closure, reduced epidermal gap, and enhanced skin barrier function compared to saline in full-thickness, splinted wounds in db/db diabetic, obese mice. Immunohistochemical (IHC) analyses of the wound tissue indicated that HRH1 and HRH 4 agonists promoted macrophage polarization, epithelial-to-mesenchymal transition, myofibroblast activation, and angiogenesis, thus activating a comprehensive pro-reparative tissue response. Overall, histamine receptor modulation demonstrated a multipronged effect on tissue repair, which offers a translationally promising therapeutic approach for diabetic wound healing.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 10","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149099676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Issue Information (Adv. Therap. 10/2026) 发行信息（第10/2026号公告）

IF 3.2 4区医学

Advanced Therapeutics Pub Date : 2026-10-06 DOI: 10.1002/adtp.70176

引用次数: 0

Correction to: “Ionic Liquid-Based Microemulsions: A Versatile Platform for Transdermal Delivery” 修正：“基于离子液体的微乳液：透皮给药的多功能平台”

IF 3.2 4区医学

Advanced Therapeutics Pub Date : 2026-09-20 DOI: 10.1002/adtp.70175

引用次数: 0

Folate-Targeted Liposomal Co-Delivery of Methotrexate and Antisense HULC for Colorectal Cancer: In Vitro Therapeutic Evaluation 叶酸靶向脂质体联合甲氨蝶呤和反义HULC治疗结直肠癌：体外治疗评价

IF 3.2 4区医学

Advanced Therapeutics Pub Date : 2026-09-17 DOI: 10.1002/adtp.202500507

Fatemeh Inanlou, Sepideh Khaleghi, Hossein Fahimi

{"title":"Folate-Targeted Liposomal Co-Delivery of Methotrexate and Antisense HULC for Colorectal Cancer: In Vitro Therapeutic Evaluation","authors":"Fatemeh Inanlou, Sepideh Khaleghi, Hossein Fahimi","doi":"10.1002/adtp.202500507","DOIUrl":"https://doi.org/10.1002/adtp.202500507","url":null,"abstract":"<div>\u0000 \u0000 <p>Colorectal cancer is mentioned as the third most common type of diagnosed malignancy worldwide. Therefore, a novel folic acid (FA)-functionalized liposomal nanocarriers containing methotrexate (MTX) and antisense lncRNA HULC were developed against HCT116 colorectal cancer cells. The fabricated nanocarrier (LDT-A) was characterized by FT-IR, DLS, AFM, and TEM devices. The hydrodynamic diameter of 102 nm and surface charge of +31 mV were measured for the LDT-A nanocarrier. The TEM indicated a size range of 100 to 150 nm, and AFM analysis confirmed the uniformity and spherical morphology of the LDT-A nanocarrier. The controlled (5% after 4 h of incubation at pH 7.4) and pH-sensitive (50% within 4 h of incubation at pH 5.0) release rate of antisense lncRNA HULC was observed. MTT assay demonstrated 14% cell viability after 72 h of treatment with 20 µg/mL of LDT-A. The IC<sub>50</sub> concentration of the nanocarrier resulted in a two to threefold reduction in the expression of IGF2BP1, SPHK1, and SLC35A3 genes involved in tumor progression. The expression of BAX (apoptosis) and mTORC1 (autophagy-related signaling) genes was enhanced by 3 and above 11 folds after treatment with nanocarrier while BCL2 (antiapoptotic) and ATG5 (autophagy) genes showed no significant change. 10. 8% apoptosis and 11.59% cell cycle arrest were observed in cancer cells after treatment with IC<sub>50</sub> concentration of LDT-A while ROS assessment exhibited 62.5% viable cells. About 99% cellular uptake was detected for FA-decorated LDT-A. These data support the potential capability of LDT-A in the suppression of colorectal cancer.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 9","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148994333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phytochemical Delivery Systems for Psoriasis: Compound-Carrier Matching, Evidence Validation, and Translational Challenges 银屑病的植物化学传递系统：化合物载体匹配，证据验证和转化挑战

IF 3.2 4区医学

Advanced Therapeutics Pub Date : 2026-09-15 DOI: 10.1002/adtp.70174

Haiyan He, Li Wan, Ming Wen, Wei Yang, Nongyue He, Libo Nie, Hongliang Tan

{"title":"Phytochemical Delivery Systems for Psoriasis: Compound-Carrier Matching, Evidence Validation, and Translational Challenges","authors":"Haiyan He, Li Wan, Ming Wen, Wei Yang, Nongyue He, Libo Nie, Hongliang Tan","doi":"10.1002/adtp.70174","DOIUrl":"https://doi.org/10.1002/adtp.70174","url":null,"abstract":"<div>\u0000 \u0000 <p>Psoriatic skin differs from healthy skin in barrier architecture, lipid organization, hydration, and local biochemical and inflammatory conditions, creating a variable environment for drug delivery. Phytochemicals investigated for psoriasis also differ substantially in solubility, stability, skin transport, systemic exposure, and safety margin. These compound-specific properties interact with the altered delivery environment of psoriatic lesions, yet existing studies often evaluate individual compounds or delivery platforms separately. This review develops a conceptual compound-to-carrier matching framework that relates the dominant pharmaceutical limitation of a phytochemical and its intended delivery context to the carrier function that requires experimental validation. Lipid carriers, microneedles, hydrogels and nanosponges, self-microemulsifying drug delivery systems, and extracellular vesicles are evaluated according to the delivery problems they address, the disease relevance of the supporting models, and the strength of the available evidence. Translational requirements related to active-material standardization, repeated-dose safety, disease-relevant tissue exposure, and manufacturing reproducibility are also examined. Most reviewed systems remain exploratory or at the preclinical validation stage, with limited evidence from human psoriatic skin and no clinical evidence identified for the delivery platforms considered. The framework therefore provides a basis for distinguishing mechanistically plausible carrier selection from experimentally validated delivery performance.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 9","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148993995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to “Formulation and Characterization of Lycopene-Loaded Microemulsion-Based Gel for the Management of Chronic Wound Healing” 更正“番茄红素微乳化凝胶治疗慢性伤口愈合的配方和特性”

IF 3.2 4区医学

Advanced Therapeutics Pub Date : 2026-09-14 DOI: 10.1002/adtp.70172

{"title":"Correction to “Formulation and Characterization of Lycopene-Loaded Microemulsion-Based Gel for the Management of Chronic Wound Healing”","authors":"","doi":"10.1002/adtp.70172","DOIUrl":"https://doi.org/10.1002/adtp.70172","url":null,"abstract":"<p>P. Popli, I. Singh, S. Basety, et al. “Formulation and Characterization of Lycopene-Loaded Microemulsion-based Gel for the Management of Chronic Wound Healing.” <i>Advanced Therapeutics</i>, <i>9</i>, no. 1 (2026): e00365. https://doi.org/10.1002/adtp.202500365.</p><p>In the original published article, Figure 6A inadvertently contains the same Day 14 image for the disease control and blank polymeric gel groups due to an error during figure assembly; the correct image has now been provided with corrections as Figure 6, and this correction does not affect the quantitative data, biochemical investigations, statistical analysis, or conclusions of the study.</p><p>Corrected Figure 6 is now given as follows:</p><p></p><p><b>FIGURE 6</b> | Efficacy Assessment: (A) Representative photographs illustrating the progression of wound closure as a percentage of the original wound area at various time points excision in treated rats. (B) Histological analysis of skin tissue from the excision wound model on day 14 post-injury, comparing (1) normal control,(2) disease control, (3) Drug dispersion, (4) Blank polymeric gel, (5) LMEG-treated groups. Key features include epidermis (E), dermis (D), ruptured stratum corneum (RSC), signs of inflammation (IF), re-epithelization (RE), and hair-follicle (HF).</p><p>We apologize for this error.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 9","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.70172","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148993975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0